Share on LinkedInShare on LinkedIn

ARTICLE · 01 AUGUST 2025

A Leading Case – Beware Sequence Errors In Patent Claims

The UK Patents Court has held that Samsung Bioepis' and Amgen's eculizumab biosimilars for treating PNH did not infringe Alexion's EP3167888, as the claims covered...

United KingdomIntellectual Property

Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc [2025] EWHC 1240 (Pat) – Mr Justice Meade – 20 May 2025

The UK Patents Court has held that Samsung Bioepis' and Amgen's eculizumab biosimilars for treating PNH did not infringe Alexion's EP3167888, as the claims covered the amino acid sequence of eculizumab including the leader sequence (which is in fact cleaved off during production of the biopharmaceutical product). Importantly, the Defendants' biosimilars of eculizumab did not comprise this leader sequence. These proceedings are a reminder that incorrect amino acid claims can be fatal in infringement proceedings – even when the commercial product is a blockbuster drug.

Background

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from